UPDATE 1-Acorda's MS walking drug Q4 sales view beats Street
* Sees Q4 Ampyra sales of $55.7 mln
* Sees FY gross sales of $141.4 mln vs est $185.12 mln
* Shares up as much as 9 percent
Jan 10 (Reuters) - Acorda Therapeutics Inc (ACOR.O) forecast better-than-expected quarterly sales view for its drug to treat walking difficulties in patients with multiple sclerosis, sending its shares up 9 percent.
The pharmaceutical company said it expects fourth-quarter sales of $55.7 million from its key drug Ampyra.
In November, Acorda had warned of a decrease in sales for Ampyra, as the number of new patients starting on the drug, which was launched in March, would no longer be augmented by patients from the backlog. [ID:nSGE6A00FY]
Analysts have, since then, revised fourth-quarter sales expectation of Ampyra to $44-$50 million.
The Hawthorne, New York-based company also said it sees gross sales of $141.4 million for the year.
Analysts, on an average, were expecting revenue of $185.12 million for the year, according to Thomson Reuters I/B/E/S.
Acorda shares, which have risen 10 percent since its warning on lower Ampyra sales, were up 7 percent at $29.48 on Monday on Nasdaq. (Reporting by Vidya L Nathan in Bangalore; Editing by Roshni Menon)
Trending On Reuters
We are living longer but not creating financial plans to keep pace. Advisers give tips on how to make sure you don’t outlive your money. Video